Pharmaceutical composition for treatment for urinary diseases comprising LPA receptor regulator
The present invention relates to a pharmaceutical composition for treatment and/or prevention for urinary diseases comprising a lysophosphatidic acid (LPA) receptor regulator. As LPA receptor regulators act on urethra and prostate, compounds acting on this receptor are useful in treating urinary diseases (urinary incontinence, dysuria, etc.). For example, an LPA receptor agonist useful for treatment of urinary incontinence, while an LPA receptor antagonist is useful for treatment of dysuria, ischuria, pollakiuria, nocturia, urodynia and benign prostatic hyperplasia.
1. A method for treatment of a urinary disease characterized by contraction of the urethra and/or prostate or characterized by occlusion of lower urinary tract, wherein the urinary disease is one or more of dysuria and pollakiuria, comprising administering to a subject having said urinary disease an amount of a lysophosphatidic acid (LPA) receptor antagonist that is effective for relaxing the urethra and/or prostate,
wherein the LPA receptor antagonist is a compound represented by formula (1), or a salt thereof:
wherein R 1 is an optionally substituted alkyl, aryl, alkyloxy, aryloxy, alkylthio, or arylthio, or is a halogen atom,
R 2 is an optionally substituted alkyl, aryl, alkyloxy, or aryloxy, or is a halogen atom,
R 3 is a hydrogen atom, lower alkyl, or alkyl halide,
R 4 is selected from the group consisting of: (a) an optionally substituted phenyl or aryl, (b) a substituted or unsubstituted alkyl, and (c) a substituted or unsubstituted alkenyl,
X is an oxygen atom, and
when R 3 is a hydrogen atom, R 4 represents a group other than methyl.
2. The method according to claim 1 , wherein the LPA receptor antagonist is methyl 3-({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl }amino) 3 -methyl-5 -isoxazolyl]benzyl}sulfanyl)propanoate.
3. The method according to claim 1 , wherein the LPA receptor is EDG-2, EDG-4 or EDG-7.
4. The method according to claim 3 , wherein the LPA receptor is EDG-2.
5. The method according to claim 1 , wherein the LPA receptor antagonist is administered in combination with at least one additional agent for treatment of said urinary disease.
6. The method according to claim 5 , wherein the LPA receptor antagonist and the at least one additional agent are contained in one formulation.
7. The method according to claim 5 , wherein the LPA receptor antagonist and the at least one additional agent are administrated as separate formulations.
8. The method according to claim 5 , wherein the at least one additional agent is an α1 antagonist.
9. The method according to claim 8 , wherein the α1 antagonist is at least one selected from the group consisting of terazosin hydrochloride, bunazosin hydrochloride, urapidil, tamsulosin hydrochloride, doxazosin mesilate, prazosin hydrochloride, indolamine, naftopidil, and alfzosin hydrochloride.
10. The method according to claim 5 , wherein the at least one additional agent is an anticholinergic agent.
11. The method according to claim 10 , wherein the anticholinergic agent is at least one selected from the group consisting of oxybutynin hydrochloride, bethanechol chloride, propiverine hydrochloride, propantheline bromide, methylbenactyzium bromide, scopolamine butylbromide, tolterodine tartrate, trospium chloride, Z-338, UK-112166-04, KRP-197, darifenacin and YM-905.
12. The method according to claim 5 , wherein the at least one additional agent is a 5α-reductase inhibitor.
13. The method according to claim 12 , wherein the 5α-reductase inhibitor is finasteride.
14. The method according to claim 5 , wherein the at least one additional agent is an antiandrogen agent.
15. The method according to claim 14 , wherein the antiandrogen agent is at least one selected from the group consisting of oxendolone, osaterone acetate and bicalutamide.
16. The method according to claim 1 , wherein said dysuria is dysuria associated with benign prostatic hyperplasia.